Pharming reports positive Phase II leniolisib topline in PIDs
Pharming said it posted positive topline Phase II data for leniolisib in genetically defined PIDs with immune dysregulation, citing a mean 26.4% spleen volume reduction and no new safety signals. Additional data is planned for ESID 2026, and CVID topline is expected in Q4 2026.
Pharming reported positive topline Phase II data for leniolisib in genetically defined PIDs with immune dysregulation, showing a mean 26.4% spleen volume reduction and no new safety signals. Additional data will be presented at ESID 2026, and CVID topline is expected in Q4 2026.